



CaroGen Management to Speak at The World Vaccine & Immunotherapy Congress

Farmington, CT, September 5, 2022– CaroGen Corporation (<https://carogencorp.com>), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that Bijan Almassian, PhD, President & CEO, and Timur Yarovinsky, MD, PhD, Vice President of Discovery, have been invited to speak at The World Vaccine & Immunotherapy Congress from November 28 to December 1, 2022 in San Diego, California (<https://www.terrapinn.com/conference/world-vaccine-immunotherapy-congress-west-coast/index.stm>). This meeting draws together global scientific and industry leaders developing novel approaches to prevention and treatment of infectious diseases and cancer.

Dr. Almassian will present data on CARG-2020, CaroGen’s lead clinical candidate. CARG-2020 is an oncolytic artificial virus delivering three transgenes: IL-12 to amplify cancer killing property of virus; IL-17A antagonist to inhibit inflammation and tumor growth; and small hairpin RNA (shRNA) to suppress the programmed death ligand 1 (PD-L1) and reverse T cell immune exhaustion. CARG-2020 proof-of-concept safety and efficacy has been established in multiple solid tumor models including colorectal, ovarian, liver, melanoma, and breast cancer. By engaging three immune signaling pathways, CARG-2020 immunotherapy results in elimination of primary tumors and prevention of tumor recurrence.

“Working through multiple mechanisms of action CARG-2020 has shown impressive effectiveness in treatment and prevention of solid tumor recurrence and significant survival advantage in multiple solid tumor models,” said. “We believe that CARG-2020 has the potential to become an important new therapeutic alternative for patients treated with other modalities and in remission,” said Dr. Almassian.

Dr. Yarovinsky will present data on CARG-201, CaroGen’s clinical candidate for treatment of chronic hepatitis B virus (HBV). CARG-201 works through the co-expression of two antigens of HBV and the induction of potent HBV-specific T cell and antibody immune responses. In an animal model of HBV persistence, dosing with CARG-201 led to significant reduction of HBV viral load.

“The development of CARG-201 as a novel HBV immunotherapy is a collaborative effort between CaroGen, Yale University and Albany Medical College scientists, who collectively have received over \$10 million in

NIH/NIDDK, NIH/NIAID and the Department of Defense funding to progress towards cGMP production and IND filing,” said Dr. Valerian Nakaar, CSO and co-founder of CaroGen.

About CaroGen Corporation

CaroGen, based in Farmington, CT, is creating a portfolio of immunotherapies and vaccines for oncology and infectious diseases using its patented [AVIDIO](#) immunotherapy platform, discovered at Yale University School of Medicine by Professor John Rose, Ph.D., a renowned virologist and CaroGen co-founder, and exclusively licensed by Yale to CaroGen for worldwide use.

Contact information:

Bijan Almassian, Ph.D.

President and CEO

balmassian@carogencorp.com

Tel: 203-815-5782